Is HDFC AMC a Good Buy in 2025?

Deciding whether HDFC Asset Management Company (HDFC AMC) is a good buy in 2025 depends on various factors, including its financial performance, market conditions, valuation, and your investment goals and risk tolerance. Below is an analysis based on available information, followed by key considerations to help you make an informed decision.

Why HDFC AMC Could Be a Good Buy

Strong Financial Performance:

Profit Growth: HDFC AMC reported a net profit of ₹2,460.19 crore in 2025, with a year-over-year (YoY) profit growth of 26.6% and sales growth of 28.3%. Quarterly profit for Q1 FY 2024 was ₹477.5 crore, up 52% YoY.

High Margins: The company maintains a strong operating profit margin (OPM) of 75%, reflecting operational efficiency.

Dividend Yield: HDFC AMC declared a dividend of ₹90 in Q1 2025, offering a yield of 3.16%, which is attractive for income-focused investors.

Market Leadership:

HDFC AMC is one of India’s largest mutual fund houses, managing ₹7,80,967 crore in assets under management (AUM) as of March 31, 2025.

Its market capitalization of ₹1,10,000 crore is more than twice that of its nearest competitor, Nippon AMC, indicating a dominant position in the asset management industry.

Growth Potential:

The mutual fund industry in India is underpenetrated, with significant room for growth as wealth shifts from traditional investments (e.g., fixed deposits) to equity markets.

HDFC AMC’s focus on innovative products, like the HDFC Innovation Fund (launched in 2025, with 80% allocation to equity), positions it to capitalize on market trends.

Analysts predict steady share price growth from 2025 to 2030 due to its strong fundamentals and industry tailwinds.

Strong Returns from Funds:

HDFC AMC’s mutual funds, such as the HDFC Mid-Cap Opportunities Fund (18.95% returns) and HDFC Flexi Cap Fund (38.39% 5-year CAGR), demonstrate a robust track record, enhancing its brand and AUM growth potential.

Risks and Considerations

High Valuation:

As of June 20, 2025, HDFC AMC is considered overvalued based on intrinsic value estimates, with a price-to-earnings (P/E) ratio of 45. This implies it could take 45 years to recover the current share price (₹5,028 as of June 25, 2025) if earnings remain static, though earnings growth (7% annually) mitigates this concern.

High valuations may limit short-term upside and increase downside risk if market sentiment shifts.

Market Correction:

The equity AUM for the industry corrected by 9.4% between October 2024 and January 2025, leading to a 5% cut in earnings per share (EPS) estimates for FY26/27. This indicates sensitivity to market volatility.

A 25% fall from its peak share price (prior to February 2025) suggests potential for further corrections if market conditions worsen.

Promoter Holding:

Promoters slightly reduced their stake from 52.48% to 52.47% in Q1 2025, which may signal minor confidence adjustments, though the change is negligible.

Competition:

While HDFC AMC is a market leader, competitors like Nippon India AMC are considered strong contenders, potentially challenging market share.

Equity Market Risks:

As an asset management company, HDFC AMC’s performance is tied to equity market trends. A bear market could reduce AUM and revenue, impacting profitability.

Key Factors Not to Ignore

Risk Tolerance: Equity investments in AMC stocks like HDFC AMC are volatile. Ensure your risk appetite aligns with potential price fluctuations.

Investment Horizon: A long-term horizon (5+ years) is ideal, given the high P/E and market volatility. Short-term investors may face risks from corrections.

Valuation Analysis: Compare HDFC AMC’s P/E (45) with peers like Nippon India or Motilal Oswal (e.g., Motilal’s P/E of 16 is significantly lower).

Market Trends: Monitor equity market performance and mutual fund inflows, as these directly affect HDFC AMC’s AUM and revenue.

Diversification: Avoid over-allocating to a single stock. Balance your portfolio with other sectors to mitigate risk.

Is HDFC AMC a Good Buy in 2025?

Bull Case: HDFC AMC is a strong buy for long-term investors with high risk tolerance, given its market leadership, robust financials, and growth potential in India’s mutual fund industry. The 3.16% dividend yield and expected share price growth (2025–2030) add to its appeal.

Bear Case: The stock’s high P/E ratio (45) and recent market corrections suggest it may be overvalued, posing risks for short-term investors or those seeking undervalued opportunities.

Recommendation: If you’re a long-term investor seeking exposure to India’s growing financial sector, HDFC AMC is a compelling option, but consider waiting for a price dip to improve entry valuation. For conservative investors, explore peers with lower P/E ratios (e.g., Motilal Oswal) or diversify through mutual funds.

Why Equity is Better than Fixed Deposits and Key Considerations

 Equity investments, such as stocks or equity mutual funds, typically offer higher long-term returns compared to fixed deposits (FDs), which provide stable but lower returns (e.g., 5–7% annually in India). Equities have the potential for capital appreciation and can outpace inflation, preserving purchasing power. For instance, Indian equity markets (e.g., Sensex) have historically delivered 12–15% annualized returns over decades. Equities also offer dividends, adding to returns, and are more tax-efficient, with long-term capital gains (LTCG) taxed at 12.5% (above ₹1.25 lakh annually) compared to FD interest, taxed at slab rates. Additionally, equities provide flexibility to adjust investments based on market conditions, unlike FDs, which lock funds for fixed tenures.

What Not to Ignore When Investing in Equity

  1. Risk: Equities are volatile; prices can fluctuate significantly in the short term. Assess your risk tolerance before investing.
  2. Time Horizon: Equity investments require a long-term perspective (5+ years) to ride out market volatility.
  3. Research: Avoid investing without understanding the company or fund. Analyze fundamentals, management, and market trends.
  4. Diversification: Don’t put all funds in one stock or sector; diversify to mitigate risk.
  5. Costs: Watch out for high fees in mutual funds or excessive trading costs, which can erode returns.
  6. Market Timing: Avoid trying to time the market; consistent investing (e.g., via SIPs) is more effective.
  7. Emotional Discipline: Don’t let fear or greed drive decisions; stick to a planned strategy.

By balancing the potential for higher returns with these considerations, equity investments can be a powerful wealth-building tool compared to fixed deposits.

Common mistakes to avoid when investing in mutual funds

 

When investing in mutual funds, there are several common mistakes and practices to avoid in order to make sound investment decisions and maximize your returns. Here are some "what not to do" guidelines in mutual fund investing:

  1. Not Setting Clear Financial Goals: Avoid investing in mutual funds without a clear understanding of your financial goals. Determine why you are investing, whether it's for retirement, education, a home purchase, or another objective.

  2. Ignoring Risk Tolerance: Don't invest in funds that are too risky or too conservative for your risk tolerance. Assess your risk tolerance honestly and choose funds that align with it.

  3. Market Timing: Avoid trying to time the market. Timing the market is extremely difficult and often leads to poor results. Instead, focus on a long-term investment strategy.

  4. Frequent Trading: Avoid excessive trading or trying to "chase" short-term market trends. Frequent trading can lead to higher transaction costs and capital gains taxes.

  5. Ignoring Costs: Don't ignore the expenses associated with mutual funds. High expense ratios can erode your returns over time. Look for funds with reasonable costs.

  6. Overlooking Diversification: Not diversifying your investments is a common mistake. Diversification helps spread risk. Avoid putting all your money into a single fund or asset class.

  7. Ignoring Asset Allocation: Asset allocation is crucial. Avoid allocating your assets in a way that's not in line with your investment goals and risk tolerance. Properly balance your investments between equities, bonds, and other asset classes.

  8. Chasing Performance: Avoid investing in a fund solely because it has recently performed well. Past performance is not a reliable indicator of future results.

  9. Neglecting Research: Don't invest in funds without doing thorough research. Review the fund's prospectus, historical performance, and the fund manager's experience.

  10. Not Monitoring Your Investments: Don't forget to periodically review and rebalance your portfolio. Market conditions change, and your asset allocation may drift from your desired mix over time.

  11. Panic Selling: Avoid making impulsive decisions during market downturns. Panic selling when the market is down can lead to significant losses. Stick to your investment strategy.

  12. Not Considering Tax Implications: Failing to consider the tax consequences of your investments can lead to unexpected tax bills. Understand the tax implications of your mutual fund holdings.

  13. Relying Solely on One Fund: Avoid putting all your investments in a single mutual fund, even if it's a well-regarded fund. Diversify across different funds and asset classes.

  14. Not Consulting a Financial Advisor: If you are unsure about your investment choices, don't hesitate to seek advice from a qualified financial advisor who can provide personalized guidance.

  15. Neglecting Changes in Your Financial Situation: Your financial situation can change over time, so don't forget to adjust your investment strategy as needed.

Remember that mutual fund investing should be part of a broader financial plan, and it's important to stay informed, diversify your investments, and maintain a long-term perspective. Making informed, well-considered decisions is key to successful mutual fund investing


How to choose a fund

  1. Alignment with Financial Goals: When a fund aligns with your financial goals, risk tolerance, and investment horizon, it is more likely to help you achieve your specific objectives, whether they are long-term wealth accumulation, retirement planning, or funding a major expense like a home purchase or education.

  2. Risk Management: Funds that meet your risk tolerance ensure you don't take on more risk than you are comfortable with. This can prevent panic selling during market downturns and help you stay invested for the long term.

  3. Diversification: Funds that offer diversification spread your risk across different asset classes, reducing the impact of a poor-performing investment. A well-diversified fund can help stabilize your portfolio and reduce overall risk.

  4. Cost Efficiency: Funds with lower expense ratios minimize the impact of fees on your returns over time, leaving more of your money invested and working for you.

  5. Professional Management: Funds with experienced and skilled fund managers can make informed investment decisions, potentially outperforming the market and helping you achieve better returns.

  6. Tax Efficiency: Funds that consider tax implications can help you minimize the tax burden on your investments, potentially saving you money in the long run.

  7. Historical Performance: While past performance doesn't guarantee future results, a fund that has demonstrated consistent performance in various market conditions can provide you with confidence that the fund's strategy is effective.

  8. Exit Load and Liquidity: Understanding the fund's exit load or redemption fee can help you avoid unnecessary charges, and a fund with good liquidity allows you to easily buy or sell your shares.

Top 10 Indian companies with high market cap and consistent growth

 

Here are the top 10 Indian companies with high market capitalization and consistent growth

  1. Reliance Industries Limited (RIL): RIL is India's largest private sector company by market capitalization, with a market cap of over INR 14 trillion. The company operates in various sectors, including oil and gas, petrochemicals, retail, and telecommunications.

  2. Tata Consultancy Services Limited (TCS): TCS is the largest software services company in India, with a market cap of over INR 13 trillion. The company provides IT services, digital, and business solutions to clients across various industries.

  3. HDFC Bank Limited: HDFC Bank is one of India's largest private sector banks, with a market cap of over INR 8 trillion. The bank provides a wide range of financial products and services to retail and corporate customers.

  4. Infosys Limited: Infosys is a global leader in technology and consulting services, with a market cap of over INR 6.5 trillion. The company provides software development, maintenance, and independent validation services to clients across various industries.

  5. Housing Development Finance Corporation Limited (HDFC): HDFC is one of India's largest housing finance companies, with a market cap of over INR 5.5 trillion. The company provides various financial products and services related to housing and real estate.

  6. ICICI Bank Limited: ICICI Bank is one of India's largest private sector banks, with a market cap of over INR 5 trillion. The bank provides a wide range of financial products and services to retail and corporate customers.

  7. Kotak Mahindra Bank Limited: Kotak Mahindra Bank is a private sector bank with a market cap of over INR 3.5 trillion. The bank provides various financial products and services to retail and corporate customers.

  8. Bajaj Finance Limited: Bajaj Finance is a non-banking financial company (NBFC) with a market cap of over INR 3.5 trillion. The company provides a wide range of financial products and services, including consumer finance, SME finance, and commercial lending.

  9. Hindustan Unilever Limited (HUL): HUL is India's largest consumer goods company, with a market cap of over INR 3.2 trillion. The company offers various consumer products, including personal care, home care, and foods and beverages.

  10. State Bank of India (SBI): SBI is India's largest public sector bank, with a market cap of over INR 2.5 trillion. The bank provides a wide range of financial products and services to retail and corporate customers.

Pidilite Industries: Building a Better Future: The Success Story of Pidilite Industries

 

Pidilite Industries Limited is an Indian multinational company that is primarily engaged in the manufacture of adhesives, sealants, construction chemicals, and other industrial chemicals. The company was founded in 1959 by Balvant Parekh and has its headquarters in Mumbai, India.

Pidilite's most well-known brand is Fevicol, which is the largest selling adhesive in India and has become synonymous with adhesives in the country. The company's other popular brands include M-Seal, Fevikwik, Fevistik, and Dr. Fixit.

Apart from adhesives and sealants, Pidilite Industries also produces a wide range of industrial chemicals such as synthetic resins, organic pigments, and surfactants. The company's products are used in various industries such as construction, automotive, packaging, textiles, and woodworking, among others.

Pidilite Industries has a strong presence not only in India but also in other countries such as the United States, the United Kingdom, Brazil, Thailand, and the Middle East. The company is known for its innovative and high-quality products and has won several awards for its performance and sustainability initiatives.

 Pidilite Industries fundamental data

 

  • Market Capitalization: INR 1.2 trillion (approx. USD 16.5 billion)
  • Revenue: INR 9,611 crore (approx. USD 1.3 billion)
  • Net Profit: INR 1,549 crore (approx. USD 211 million)
  • Earnings per share (EPS): INR 13.85
  • Price to Earnings (P/E) Ratio: 73.18
  • Return on Equity (ROE): 24.76%
  • Debt to Equity Ratio: 0.17
  • Dividend Yield: 0.28%

It's worth noting that these figures are subject to change depending on the company's performance and the prevailing market conditions.

Buy or sell?

Pidilite Industries is a well-established company with a strong brand reputation, a diverse product portfolio, and a global presence. The company has a dominant market position in India and is expanding its international operations. Moreover, Pidilite has a track record of innovation and continuous product development, which is essential for staying competitive in the industry.

On the other hand, it's important to note that the company operates in a highly competitive market, and there are always risks associated with investing in the stock market. The price of Pidilite Industries' stock may fluctuate depending on various factors such as economic conditions, changes in government policies, currency fluctuations, and competition.

Therefore, before making any investment decision, it's important to consider your investment objectives, risk tolerance, and consult a financial advisor. You should also conduct thorough research on the company's financial performance, market trends, and other relevant factors before making any investment decision.

Procter & Gamble Hygiene and Health Care Ltd

Procter & Gamble Hygiene and Health Care Ltd

P&G Hygiene and Health Care is one of India's fastest growing Fast Moving Consumer Goods Companies incorporated on 20th July 1964. Earlier known as Richardson Hindustan (RHL), in 1964 company received Industrial License to undertake manufacture of Menthol and de-mentholised peppermint oil and VICKS range of products such as Vicks VapoRub, Vicks Cough Drops and Vicks Inhaler.
Later in the year 1967 RHL introduced CLEARASIL, back then America's number one pimple cream. In 1985 RHL became affiliate of The Procter & Gamble Company, USA.
In 1989 the name of the company was changed to Procter & Gamble India and launched sanitary napkin under the name Whisper bringing a sudden change in Indian feminine hygiene category.
In June 2002, Procter & Gamble Hygiene & Health Care announced the launch of New Improved Vicks VapoRub – India’s Number One Cold Rub – that provides multi-symptom relief from the six symptoms of a child’s cold, namely – blocked nose, cough, body ache, headache, muscle-stiffness and breathing difficulty.
In July 2002, Procter & Gamble announced the launch of Vicks Action500+ Night tablets, a specially designed cold medicine that gives consumers multi-symptom relief from bothersome cold symptoms like headache and breathing difficulty, hence allowing restful sleep at night.
In October 2002, India’s number one cough and cold brand – Vicks – celebrated its 50th Year in India and launched Dual Golden Jubilee Offers to reward Indian consumers for 50 Years of trust and loyalty.
Globally Procter & Gamble owns brands like Duracell, Olay, Tide, Gillette, Braun, Pringles, Lacoste, Puma, Oral-B, HUGO, Mr.Clean, Cover Girl, Pantene Pampers ,Old spice are amongst others. Currently P&G Hygiene and Health has portfolio of brands such as Vicks & Whisper.
Products
Vicks- It is India’s No.1 Cough and Cold Brand. It created the cold & cough over-the-counter (OTC) category in India way back in 1952 and has led the category till date. Under this brand it has introduced products namely Vicks Action500+, Vicks VapoRub, Vicks Cough Drops, Vicks Formula 44 Cough Syrup and Vicks Inhaler.
Whisper- Under this it has introduced products for feminine hygiene. It has introduced products such as Whisper Maxi Regular, Whisper Maxi XL Wings, Whisper Ultra with Wings and Whisper Choice.
Awards and recognition
Vicks was rated as ‘India’s Most Trusted Brand’ by the ‘Advertising & Marketing’ Magazine
P&G Hygiene and Health Care was voted India's Best Employer 2003 in a survey of 200 companies conducted by International HR Consultancy Hewitt Associates in association with Business Today magazine.

Market Cap: 32,337 Cr.
Current Price: 9,962
52 weeks High / Low 11000.00 / 8714.00
Book Value: 248.15
Stock P/E: 80.21
Dividend Yield: 0.40 %
ROCE: 89.10 %
ROE: 56.85 %
Sales Growth (3Yrs): 1.71 %
Listed on BSE and NSE
Company Website
Face Value: 10.00


Industry PBV:
EPS: 124.19
Graham: 832.71
Debt to equity: 0.00
Book value: 248.15
Price to Earning: 80.21
PEG Ratio: 6.27
Earning Power: 43.79 %
Return on equity: 56.85 %
Pledged percentage: 0.00 %
Intrinsic Value: 12,452
Industry PE:
Piotroski score: 8.00
Volume: 1,198
Market cap to quarterly profit: 224.39
Market Capitalization: 32,337 Cr.
Price to book value: 40.15
Return on assets: 52.87 %
Debt: 0.00 Cr.
Interest Coverage Ratio: 118.20
Promoter holding: 70.64 %
Unpledged promoter holding: 70.64 %
Sales last year: 2,455 Cr.

Pfizer

Pfizer

Pfizer came to India in 1950 through a company named Dumex. Its first production unit was set up at Darukhanna in Mumbai. It manufactured products like Protinex, Isonex, Becosules and Corex.In the year 1960, the company set up one more plant at Thane, near Mumbai for manufacturing and conducting product research. In 1965 Pfizer entered into a licence agreement with Pfizer Corporation for the use of Pfizer’s processes, technical know-how, etc to manufacture its existing products. Later in the year 1992, Dumex was amalgamated with Pfizer.
In India, Pfizer instituted the first ever Disease Management Programme -- Healthy Heart in Cardio Vascular Disease (Hypertension, Chronic Stable Angina and Dyslipidemia), in partnership with Apollo Hospital, Hyderabad and Apollo Hospital, Chennai 
Six Pfizer brands feature among the Top 100 pharmaceutical brands in India, while two of Pfizer India's brands -- Corex (Cough Formulation) and Becosules (Multivitamin) -- continue to rank among the Top 15 pharmaceutical drug brands
The company’s manufacturing plant was ISO 14001 certified for its Environment Management System awarded by DNV Certification B.V, Netherlands.
In 2013 Pfizer Ltd and Wyeth Ltd decided to merge, creating a single Pfizer Brand.
Products
Prescription Drugs- Pfizer manufactures prescription drugs such as Viagra, Lyrica, Viagra, Dolonex Gel, Ponstan, Citralka Liquid, and many more.
Consumer Health- It produces over the counter formulations and drugs such as Benadryl cough, Coolmint Listerine Mouthwash, Rashfree, Caladryl, Sloans Balm, etc.
Animal Health- It manufactures products for animal care namely Amoxisol, Vanguard 5/L, Stafac, Furea, Qualidrops, Catosal, Bayrocin, Nutrimilk, etc.
Awards
In March 2011 Pfizer ranked first in the medicine and health care industry in an annual ranking conducted by Antal International, a global executive search firm.
In 2010 December Pfizer France Wins Oncology Medical Affairs Best Practice Award.
In a survey conducted by Ernst & Young on customer satisfaction, Pfizer was ranked HIGH in terms of Overall Satisfaction with the Services and Interactions.
The company was acknowledged for its product Exubera with 'Innovative Products of the Year' at Pharma Excellence Awards 2006
It received the Silver Award for its printing advertising on Gelusil brand at the ABBY-All India Awards for Creative Excellence.

Market Cap: 12,189 Cr.
Current Price: 2,664
52 weeks High / Low 3840.00 / 2050.60
Book Value: 604.61
Stock P/E: 32.13
Dividend Yield: 0.75 %
ROCE: 21.48 %
ROE: 14.11 %
Sales Growth (3Yrs): 2.04 %
Listed on BSE and NSE
Company Website
Face Value: 10.00


Industry PBV:
EPS: 82.92
Graham: 1,062
Debt to equity: 0.00
Book value: 604.61
Price to Earning: 32.13
PEG Ratio: 2.71
Earning Power: 15.30 %
Return on equity: 14.11 %
Pledged percentage: 0.00 %
Intrinsic Value: 3,597
Industry PE:
Piotroski score: 6.00
Volume: 9,777
Market cap to quarterly profit: 127.24
Market Capitalization: 12,189 Cr.
Price to book value: 4.41
Return on assets: 13.87 %
Debt: 2.50 Cr.
Interest Coverage Ratio: 1,226
Promoter holding: 63.92 %
Unpledged promoter holding: 63.92 %
Sales last year: 1,969 Cr.

Glaxosmithkline Pharmaceuticals Ltd.

GlaxoSmithKline Pharmaceuticals Ltd.

Established in the year 1924 in India, GlaxoSmithKline Pharmaceuticals Ltd. (GSK Rx India) is one of the oldest pharmaceuticals company and employs over 3,500 people. Globally, the company is a £28.4 billion, leading, research-based healthcare and pharmaceutical company. In India, it is one of the market leaders with a turnover of Rs 2080 crore and a share of 5.1%. GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer.
The company leads in several therapeutic segments - dermatology, anti-helmentics, and hormones. It has 7 products in the top 50 brands, and the top five GSK products are Augmentin, Calpol, Ceftum, Phexin, and Betnesol. The company's vaccines division is ranked first in a fast-growing vaccines market. Some leading products in India are Havrix, Varilrix, Rotarix, Hiberix and Cervarix.
GSK India's R&D centres at Thane and Nashik have been granted recognition by the Department of Scientific and Industrial Research, Government of India. The number of clinical studies conducted in India is rapidly growing across a range of therapy areas. The company's social responsibility programmes focus on development of under developed villages, women, children and aged, specifically in the areas of healthcare and education.
The GSK India product portfolio includes prescription medicines and vaccines. Our prescription medicines range across therapeutic areas such as anti-infectives, dermatology, gynaecology, diabetes, oncology, cardiovascular disease and respiratory diseases. The company is the market leader in most of the therapeutic categories in which it operates. GSK also offers a range of vaccines, for the prevention of hepatitis A, hepatitis B, invasive disease caused by H, influenzae, chickenpox, diphtheria, pertussis, tetanus, rotavirus, cervical cancer and others.
The company's best-in-class field force, backed by a nation-wide network of stockists, ensures that the Company's products are readily available across the nation. The company has two manufacturing units in India, located at Nashik and Thane as well as a clinical development centre in Bangalore. The state of art plant at Nashik makes formulations while bulk drugs and the active pharmaceutical ingredients are manufactured at Thane.
Products
Prescription medicines
The GSK India product portfolio includes prescription medicines and vaccines. The company is a market leader in most of the prescription medicines.
·      Analgesic
·      Anti-Infective
·      Anti-Inflammatory
·      Anti-Parasitic
·      Cardiovascular
·      Dermatology
·      Diabetes
·      Endocrine
·      Gastrointestinal
·      Gynaecology
·      Immunosupressants
·      Nutritional
·      Respiratory
·      CNS
·      Oncology
Vaccines
The company's vaccines division is the leader in fast growing vaccine market. It provides vaccines for prevention of hepatitis A, hepatitis B, invasive disease caused by H, influenzae, chickenpox, diphtheria, pertussis, tetanus and others. Brands like Engerix-B, Havrix, Priorix, Twinrix are some vaccines created by GSK India.
The company was awarded  for the “Multi Cultural Diversity Award” from GlaxoSmithKline Consumer Healthcare, US as an appreciation for the ‘Famili Vaccines’ Programme. The company in 2008 launched two vaccines for dphtheria, ttanus and acellular prtussis (DTP) namely Boostrix and Infanrix. DTP vaccines are part of the routine immunization in over 100 developed and developing countries.
Infanrix is used for childhood immunization against Diphtheria, Tetanus and Pertussis for newborns from the sixth week of age. Boostrix is used for children above seven years of age, adolescents and adults and will boost the waning immunity against Diphtheria, Tetanus and Pertussis.
Milestones
1919 - Trading links with India established
1924 - H J Foster & Co appointed sole agents
1926 - Foster's becomes wholly-owned subsidiary of Joseph Nathan
1947 - Secondary manufacture commences after war
1950
·      Name changed to Glaxo Laboratories
·      SmithKline & French appoints its first medical representative
1956 - Primary production of vaccines begins at Worli
1960's
·      Infant foods manufactured at milk drying plant at Aligarh
·      Manufacturing facility for pharmaceuticals opened in Mumbai
1961 - Vitamin A and betamethasone manufactured at new plant at Thane using imported raw materials
1968 - Registered as a limited company. Animal health products introduced
1969 - Indian shareholders acquire 25 per cent of the company's equity
1971
·      Research and development laboratory built at Thane
·      Relocation of the SmithKline and French plant from Mumbai to Bangalore
1983 - Glaxo Group equity reduced from 75 per cent to 40 per cent Nashik factory commissioned
1984 - SmithKline & Beecham becomes a public limited company under the new name of Eskayef Limited. Plant set up in Mysore for manufacture of bulk drugs
1985 - The company's second basic drugs factory was inaugurated at Ankleshwar, Gujarat
1986 - Joint venture projects Vegepro Foods and Feeds Limited and K G Gluco Biols were launched with equity participation of around 24 per cent by Glaxo India
1987 - The company's name changed to Glindia Limited
1988
·      Production of bulk drug Ranitidine commenced at Ankleshwar
·      Hindustan Foods Limited, a joint venture project for the manufacture of extruded foods, was commissioned at Usgao, Goa with equity participation of 20 per cent by Glaxo and its subsidiaries
1989
·      Production of Zinetac at Nashik commenced
·      The company's name changed to Glaxo India Limited
1990
·      Production of the bulk drug, cephalexin, commenced at Ankleshwar and the salbutamol inhalers at Nashik
·      Glaxo rated amongst the first five of India's most respected companies (4th place), in a survey by Businessworld magazine
1991
·      An agreement was signed with the Council of Scientific and Industrial Research
·      Production of the bulk drug Griseofulvin commenced at Ankleshwar
·      Facilities commissioned at Nashik for the sterile dry filling of the injectable cephalosporins cefuroxime sodium and ceftazidime pentahydrate
1992
·      Liquid injectables block commissioned at Nashik
·      The company's trade investment in Vegepro and Feeds Limited was sold
1993
·      Glaxo Group raised its equity from 40 per cent to 51 per cent
·      The company sold its investment in Hindustan Foods Limited and Dempo Dairy Industries Limited
·      Cetzine, a second generation anti-histamine, and research product of UCB Pharma (Belgium), was launched under a co-marketing agreement
·      The company launched two anti-TB products - Zucox and Rizap
·      Manufacture of Beclomethasone inhalers commenced at Nashik
·      Thane Factory's new fermentation plan was inaugurated, making this site the largest Betamethasone producer in Glaxo Group
·      The company received recognition from the Ministry of Commerce as an export house
1994
·      Glaxo - Ankleshwar wins the Chief Executive's Trophy for Health Safety and Environment Management
·      Glaxo rated as India's 44th most valuable company in a survey conducted by Business Today
·      The company sold its Family Products Division to H J Heinz for a sum of Rs 210 crores. A formal agreement between the companies was signed and transaction was completed in October
1995
·      Glaxo - Thane won the Chief Executive's Trophy for Health Safety and Environmental Management
·      The company declares a Bonus in the ratio of 1:1
·      Voluntary Retirement Scheme introduced for Management Staff 1996 - 175 per cent record dividend declared
·      Change in distribution system - a Voluntary Retirement Scheme introduced at Branches and Depots
·      Government approved state-of-the-art Pharmacy Research & Development Centre (PR&D) inaugurated at Thane to cater to the unmet medical needs and to exploit local commercial opportunities
·      Glaxo rated amongst the top ten of India's most respected companies (8th place) in the Business World - Marg survey
·      Glaxo wins 'Marketing Company of the Year' award from the Institute of Marketing & Management (IMM)
·      Glaxo wins 'The Analyst' award from Chartered Analyst magazine as an investor rewarding company.
·      SmithKline Beechams Bangalore plant awarded the ISO 9002 certification
1997
·      Voluntary Retirement Scheme introduced for workmen at Worli and Thane
·      Glaxo acquires Biddle Sawyer Group of Companies subject to statutory approvals
1998
·      Biddle Sawyer acquisition is completed
·      Worli factory completes two million man-hours free from lost time accident
·      Gramin Arogya Vikas Sanstha - a rural development programme initiated in Nashik
·      Glaxo ranks 21st in Business Today's list of 500 most valuable companies
1999
·      Glaxo India completes 75 years of its operations in India
·      Glaxo India ranked as India's Most Respected Company by BusinessWorld. Glaxo took the top honour from amongst 229 companies surveyed by BusinessWorld - Indica Research
·      Glaxo India wins two Chairman's Awards for the year 1998 (announced in 1999) - The company's Community Support Programme won the Chairman's Award for 'Excellence in Corporate Citizenship' and Glaxo India's Nashik Factory was chosen for the Health, Safety and Environmental Management Award
·      Nashik factory completes three million man-hours free from lost time accidents
·      Winner of the 1999 IMM (Institute of Marketing and Management) Award for Excellence as Marketing Company (organised sector)
·      The company's HIV / AIDS campaign in Press wins the first prize for the best 'Social Responsibility Communication', awarded by the Association of Business Communicators of India (ABCI)
·      The Positive People Campaign entitled 'Real Friendships Don't Die with HIV' also wins the Global Award from the New York Festivals
2000
·      Agrivet Farm Care (AFC) tied up with Merial, the world's largest Animal Health Company, to market poultry vaccines
·      Glaxo India ranked 6th in 'Business Today' - Stern Stewart & Co. listing of India's best Wealth Creator Companies
·      Launches Seretide for Asthma
2001
·      Merger of SmithKline Beecham Pharmaceuticals (India) Limited into Glaxo India Limited. The name of the company changed to GlaxoSmithKline Pharmaceuticals Limited in India
2002
·      J P Garnier inaugurates GSK House
·      VRS at the Ankleshwar site and sale of Ankleshwar property to Glenmark Pharmaceuticals Limited
2003
·      GlaxoSmithKline named as India's most respected Pharmaceutical Company in a survey conducted by BusinessWorld and the Indian Market Research Bureau (IMRB)
·      Launches Cetzine (cetirizine; anti-histamine), Zimig (terbinafine; anti-infective), CCM (calcium citrate maleate; nutritional), Cobadex CZS (multivitamin with trace elements)
2004
·      Augmentin becomes the No. 1 pharmaceutical brand, as rated by IMS
·      Launches Priorix (measles, mumps, rubella vaccine)
·      Receives prestigious Multi Cultural Diversity Award from GlaxoSmithKline Consumer Healthcare Limited, U.S. for the Famili Vaccines programme, selected from 83 entries received from markets world-wide
2005
·      Foundation stone laid for GSK vaccines plant at Nashik
·      Launch of oral contraceptives: Elogen (desogestrel and ethinylestradiol) and Zerogen (progesterone only pill)
·      Enters the diabetes therapeutic segment with the launch of Windia (rosiglitazone) and Windamet (rosiglitazone and metformin)
2006
·      Augmentin grows to a Rs. 100 crore brand
·      In-licensing alliance with Eisai Pharmaceuticals, Japan and launch of Parit (rabeprazole; gastrointestinal therapy area)
·      GlaxoSmithKline divests its Agrivet Farm Care (AFC) Business
2007
·      Launches Carzec (carvedilol) and Zemetril (cefprozil)
·      GlaxoSmithKline divests its Qualigens Fine Chemicals (QFC) Business
·      Launches Arixtra (fondaparinux sodium), an antithrombotic drug used in treating Deep Vein Thromb sis (DVT) and Acute Coronary Syndrome (ACS)
2008
·      Launches Boostrix (Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed), Infanrix (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine, Adsorbed) and Rotarix (Human Rotavirus Vaccine, Live Attenuated) vaccines
·      Launches Tykerb, a drug in combination with capecitabine, is indicated for the treatment of patients with advanced or metastatic breast cancer whose tumours overexpress HER2+/neu (ErbB2+) and who have failed on prior therapy including trastuzumab
·  Launches Benitec (Olmersartan) and Benitec-H (Olmesartan + Hydrochlorothiazide) an anti-hypertensive drug in-licensed from Daiichi Sankyo Company Limited, Japan
2009
  • Launches Cervarix [Human Papillomavirus (Types 16 and 18)] vaccine
  • Launches Dermocalm for treatment of Dry Itchy skin
  • Commences Albendazole production in Nashik to treat Lymphatic Filariasis
2010
  • Launches Mycamine an injectible antifungal drug in-licensed from Astellas, Japan
  • Andrew Witty dedicates the Albendazole facility at Nashik to WHO to eliminate Lymphatic FilariasisCertificate of Merit awarded to Ankleshwar Factory for 'Excellence in Energy Conservation' by the Federation of Gujarat Mills and Industries (FGMI)
  • Voluntary Retirement Scheme introduced for Glaxo workmen
  • Eskayef Limited renamed SmithKline Beecham Pharmaceuticals India Ltd,
  • The Mysore plant receives ISO 9002 certification
  • The new Iodex plant inaugurated in Bangalore

2011
  • Most Respected Company Award - Business World
  • Launches Votrientâ„¢ indicated for the treatment of advanced renal cell carcinoma (RCC)
  • Launches Revoladeâ„¢ indicated for the treatment of thrombocytopenia (reduced platelet count) in adults with the blood disorder chronic immune (idiopathic) thrombocytopenic purpura (ITP)
  • Vaccine Market Company of the Year award - Frost & Sullivan
  • Special Commendation - Good Corporate Citizen Award 2011 - Bombay Chamber of Commerce
  • Pharma / Life - Science Supply Chain Excellence Award presented at the 5thExpress, Logistics and Supply Chain Conclave
    Unveils Synflorix - a vaccine against invasive pneumococcal disease
2012
  • Launches Altargoâ„¢ used to treat bacterial infections affecting small areas of skin
  • Introduces Volibris (Ambrisentan), a non-sulphonamide class endothelin receptor antagonist (ERA) used to treat pulmonary arterial hypertension (PAH) indicated for WHO Functional Class II & III patients in India. Volibris® is a trademark of GlaxoSmithKline. Ambrisentan has been licensed to GlaxoSmithKline by Gilead Sciences Inc.
  • GSK India named as India's most admired company in Pharmaceutical space by HAY Group and Fortune Magazine.
  • Awarded the Paediatrician's Award for the Best Vaccine Company of the Year by Frost & Sullivan.
  • Received the Dr. H. R. Nanji Memorial Marketing Excellence Award for CCM in the 'Existing Pharmaceuticals Product' category from OPPI (Organisation of Pharmaceutical Producers of India)
2013

  • Fourth CII National HR Excellence Award 2013 for 'Significant achievement in HR Excellence'
  • GSK India named as one of 'India's Most Admired Companies' by Fortune India & HAY Group
  • Business Today survey in partnership with PeopleStrong HR Services named GSK India as one of the 'Best Companies to work for'


Market Cap: 24,017 Cr.
Current Price: 1,418
52 weeks High / Low 1812.00 / 1020.00
Book Value: 112.86
Stock P/E: 60.42
Dividend Yield: 1.23 %
ROCE: 25.61 %
ROE: 16.67 %
Sales Growth (3Yrs): -4.41 %
Listed on BSE and NSE
Company Website
Face Value: 10.00


Industry PBV:
EPS: 22.70
Graham: 240.09
Debt to equity: 0.00
Book value: 112.86
Price to Earning: 60.42
PEG Ratio: -4.77
Earning Power: 15.56 %
Return on equity: 16.67 %
Pledged percentage: 0.00 %
Intrinsic Value: -1,733.38
Industry PE:
Piotroski score: 7.00
Volume: 6,566
Market cap to quarterly profit: 221.62
Market Capitalization: 24,017 Cr.
Price to book value: 12.56
Return on assets: 14.65 %
Debt: 0.99 Cr.
Interest Coverage Ratio: 1,015
Promoter holding: 75.00 %
Unpledged promoter holding: 75.00 %